Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 222) Show all publications
Venge, P., Tejera, V. C., Peterson, C., Xu, S., Larsson, A., Simrén, M., . . . Törnblom, H. (2024). Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.. Neurogastroenterology and Motility, Article ID e14984.
Open this publication in new window or tab >>Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.
Show others...
2024 (English)In: Neurogastroenterology and Motility, ISSN 1350-1925, E-ISSN 1365-2982, article id e14984Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastro-intestinal disorder characterized by discomfort with constipation and/or diarrhea with unclear pathophysiology. We aimed to determine the activities of colorectal eosinophils, neutrophils and epithelial cells by biomarkers in feces reflecting these activities.

METHODS: Fecal samples were collected from 185 patients with IBS before and after 8 weeks of placebo or mesalazine treatment and from 40 healthy subjects. Calprotectin, eosinophil derived neurotoxin (EDN), eosinophil cationic protein (ECP), human neutrophil lipocalin (HNL) (pab/765) or dimer, human phospholipase BII-precursor (HPLBII-P) and myeloperoxidase (MPO) were measured by ELISA. Symptom scores were evaluated by diaries.

RESULTS: HPLBII-P, HNL (pab/765) and EDN, proteins secreted by intestinal epithelial cells, were elevated in IBS patients as compared to healthy subjects (p < 0.0001-p = 0.008). In contrast, the neutrophil proteins calprotectin, MPO and HNL dimer were unaltered. The eosinophilic protein ECP was lower in IBS (p = 0.001). HNL (pab/765) (p = 0.01) and EDN (p = 0.004) increased in IBS patients after mesalazine treatment. Colo-rectal mucosa showed strong staining of HPLBII-P and western blotting of fecal extracts showed the presence of mainly monomeric, epithelial-associated HNL.

CONCLUSIONS: The absence of signs of involvement of neutrophils and eosinophils in IBS suggests that activity of local epithelial cells rather than inflammation may be a major determinant of the disease. The measurements of EDN, HNL (pab/765), and HPLBII-P may serve as potential fecal biomarkers in the study and monitoring of IBS.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
calprotectin, eosinophil, eosinophil cationic protein, eosinophil derived neurotoxin, human neutrophil lipocalin, myeloperoxidase, neutrophil
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-545816 (URN)10.1111/nmo.14984 (DOI)001379626700001 ()39688084 (PubMedID)
Available from: 2024-12-23 Created: 2024-12-23 Last updated: 2025-03-05Bibliographically approved
Ling Lundström, M., Peterson, C., Hedin, C. R., Bergemalm, D., Lampinen, M., Magnusson, M. K., . . . Carlson, M. (2024). Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD. Alimentary Pharmacology and Therapeutics, 60(6), 765-777
Open this publication in new window or tab >>Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD
Show others...
2024 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 60, no 6, p. 765-777Article in journal (Refereed) Published
Abstract [en]

Background: Faecal biomarkers can be used to assess inflammatory bowel disease (IBD).

Aim: To explore the performance of some promising biomarkers in diagnosing and predicting disease course in IBD.

Methods: We included 65 patients with treatment-naïve, new-onset Crohn's disease (CD), 90 with ulcerative colitis (UC), 67 symptomatic controls (SC) and 41 healthy controls (HC) in this prospective observational study. We analysed faecal samples for calprotectin (FC), myeloperoxidase (MPO), human neutrophil lipocalin (HNL), eosinophil cationic protein ECP and eosinophil-derived neurotoxin (EDN) and compared markers among groups. We assessed the diagnostic capability of biomarkers with receiver operating characteristic curves. Clinical disease course was determined for each patient with IBD and analysed the association with biomarkers by logistic regression.

Results: All markers were elevated at inclusion in patients with IBD compared with HC (p < 0.001) and SC (p < 0.001). FC (AUC 0.85, 95% CI: 0.79-0.89) and MPO (AUC 0.85, 95% CI: 0.80-0.89) showed the highest diagnostic accuracy in distinguishing IBD from SC. The diagnostic ability of biomarkers differed between IBD subtypes with the highest performance for FC and MPO in CD. The diagnostic accuracy was further improved by combining FC and MPO (p = 0.02). Levels of FC, MPO and HNL at inclusion were predictive of an aggressive disease course with MPO showing the strongest association (p = 0.006).

Conclusions: This study provides new insight into the diagnostic and prognostic capability of neutrophil and eosinophil biomarkers in IBD and suggests that MPO, alone or in combination with FC, may add to the diagnostic power of faecal biomarkers.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-535182 (URN)10.1111/apt.18154 (DOI)001270545300001 ()38997818 (PubMedID)2-s2.0-85198503570 (Scopus ID)
Funder
Swedish Research Council, 2020–02021
Available from: 2024-07-17 Created: 2024-07-17 Last updated: 2025-06-16Bibliographically approved
Venge, P., Peterson, C., Xu, S., Larsson, A., Johansson, J. & Tydén, J. (2024). HNL Dimer in plasma is a unique and useful biomarker for the monitoring of antibiotic treatment in sepsis. PLOS ONE, 19(9), Article ID e0310987.
Open this publication in new window or tab >>HNL Dimer in plasma is a unique and useful biomarker for the monitoring of antibiotic treatment in sepsis
Show others...
2024 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 19, no 9, article id e0310987Article in journal (Refereed) Published
Abstract [en]

Introduction: Sepsis is a growing problem worldwide and associated with high mortality and morbidity. The early and accurate diagnosis and effective supportive therapy are critical for combating mortality. The aim of the study was to compare the kinetics of four biomarkers in plasma in patients admitted to ICU including sepsis and during antibiotics treatment.

Methods: The biomarkers evaluated were HBP (Heparin-binding protein), HNL Dimer (Human Neutrophil Lipocalin), HNL Total and PCT (Procalcitonin). Plasma was obtained at admission to ICU and during follow-up at days 2 and 3. Antibiotic treatment was started or reviewed on admission to ICU. The results were compared to SOFA and KDIGO-scores and to survival. 277 patients admitted to ICU were included of which 30% had sepsis. The other groups were categorized as miscellaneous, other medical and trauma.

Results: The plasma concentrations of all four biomarkers were highly elevated with the highest concentrations in sepsis patients. During the follow-up period HNL Dimer decreased already day 2 and further so day 3 (p<0.00001) in contrast to unchanged concentrations of the other three biomarkers. HNL Total showed the strongest relationships to the clinical scores (p<0.0001) and was by multiples regression analysis independently related to these scores.

Conclusion: Our data supports and confirms our earlier findings of HNL Dimer being a novel and potentially useful clinical tool in antibiotic stewardship in sepsis. HNL Total reflects epithelial cell activity in the body and is an interesting biomarker for the management of organ failure in such patients.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2024
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-539361 (URN)10.1371/journal.pone.0310987 (DOI)001320777500042 ()39325799 (PubMedID)
Available from: 2024-09-27 Created: 2024-09-27 Last updated: 2024-11-07Bibliographically approved
Xu, S., Hultström, M., Larsson, A., Lipcsey, M., Lindskog, C., Bülow, S., . . . Venge, P. (2024). The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Glomerular Activity in COVID-19 and Diabetes Mellitus. Journal of Clinical Medicine, 13(9), Article ID 2540.
Open this publication in new window or tab >>The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Glomerular Activity in COVID-19 and Diabetes Mellitus
Show others...
2024 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 13, no 9, article id 2540Article in journal (Refereed) Published
Abstract [en]

Background: The human phospholipase B-II precursor (HPLBII-P) was originally purified from white blood cells but is also found in other cellular structures, such as kidney glomeruli and tubuli. The objective of this report was to investigate the relationship of HPLBII-P in urine to acute kidney injury in patients with COVID-19. Methods: Urine was collected at admission from 132 patients with COVID-19 admitted to the intensive care units (ICUs) because of respiratory failure. HPLBII-P was measured using a sensitive ELISA. For comparison, human neutrophil lipocalin (HNL) was measured in urine, using the ELISA configured with the monoclonal antibody 763/8F, as a sign of tubular affection in addition to routine biomarkers of kidney disease. Results: Overall, the concentrations of urinary HPLBII-P were almost 3-fold higher in patients with COVID-19 compared to healthy controls (p < 0.0001) and with significantly higher concentrations even in patients with COVID-19 without signs of acute kidney injury (AKI) (p < 0.001). HPLBII-P was further increased in patients with AKI (p < 0.02). HPLBII-P was significantly increased in patients with diabetes mellitus (p = 0.0008) and correlated to plasma glucose (r = 0.29, p = 0.001) and urine albumin concentrations (r = 0.55, p < 0.001). Conclusions: Urine concentrations of HPLBII-P are highly raised in the urine of patients with COVID-19 and relate to AKI and diabetes mellitus. HPLBII-P may reflect glomerular injury and/or increased glomerular cell activity in SARS-CoV-2 infections.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
KIM-1, NGAL, acute kidney injury (AKI), cystatin C, lipocalin
National Category
Infectious Medicine Anesthesiology and Intensive Care
Identifiers
urn:nbn:se:uu:diva-527862 (URN)10.3390/jcm13092540 (DOI)001221550100001 ()38731071 (PubMedID)
Available from: 2024-05-12 Created: 2024-05-12 Last updated: 2024-05-27Bibliographically approved
Xu, S., Larsson, A., Lind, L., Lindskog, C., Ärnlöv, J. & Venge, P. (2024). The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?. Journal of Clinical Medicine, 13(9), Article ID 2629.
Open this publication in new window or tab >>The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?
Show others...
2024 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 13, no 9, article id 2629Article in journal (Refereed) Published
Abstract [en]

Background: A previous report showed that the urine output of HPLBII-P in patients with diabetes mellitus and SARS-CoV-2 infection was increased as a sign of glomerular dysfunction. The aim of this report was to investigate the relation of the urine output of HPLBII-P to diabetes mellitus in two large community-based elderly populations, i.e., the ULSAM and PIVUS cohorts. Methods: HPLBII-P was measured by an ELISA in the urine of a community-based cohort of 839 men (ULSAM) collected at 77 years of age and in the urine of a community-based cohort of 75-year-old men, n = 387, and women, n = 401 (PIVUS). KIM-1, NGAL, and albumin were measured in urine and cathepsin S and cystatin C in serum. Results: HPLBII-P was significantly raised among males with diabetes in the ULSAM (p < 0.0001) and PIVUS cohorts (p ≤ 0.02), but not in the female cohort of PIVUS. In the female subpopulation of insulin-treated diabetes, HPLBII-P was raised (p = 0.02) as compared to women treated with oral antidiabetics only. In the ULSAM cohort, HPLBII-P was correlated to NGAL, KIM-1, and albumin in urine both in non-DM (all three biomarkers; p < 0.0001) and in DM (NGAL; p = 0.002, KIM-1; p = 0.02 and albumin; p = 0.01). Plasma glucose and HbA1c in blood showed correlations to U-HPLBII-P (r = 0.58, p < 0.001 and r = 0.42, p = 0.004, respectively). U-HPLBII-P and cathepsin S were correlated in the ULSAM group (r = 0.50, p < 0.001). No correlations were observed between U-HPLBII-P and serum creatinine or cystatin C. Conclusions: The urine measurement of HPLBII-P has the potential to become a novel and useful biomarker in the monitoring of glomerular activity in diabetes mellitus.

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
biomarker, nephropathy, podocyte
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-527863 (URN)10.3390/jcm13092629 (DOI)001220542000001 ()38731158 (PubMedID)
Available from: 2024-05-12 Created: 2024-05-12 Last updated: 2024-05-27Bibliographically approved
Ling Lundström, M., Peterson, C., Lampinen, M., Hedin, C. R. H., Keita, Å. V., Kruse, R., . . . Carlson, M. (2023). Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 14(8), Article ID e00605.
Open this publication in new window or tab >>Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease
Show others...
2023 (English)In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 14, no 8, article id e00605Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: 

Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown.

METHODS: 

We performed a prospective multicenter cohort study and included patients with active IBD who provided a fecal sample at initiation of biological therapy. Levels of FC, myeloperoxidase (MPO), human neutrophil lipocalin (HNL), and eosinophil-derived neurotoxin (EDN) were analyzed and related to clinical remission status at 3 months. Changes in levels of markers at 3 months were calculated, and the impact of concomitant use of corticosteroids at baseline was estimated.

RESULTS: 

In patients achieving clinical remission (n = 27), a decrease in levels of FC (P = 0.005), MPO (P < 0.001), HNL (P < 0.001), and EDN (P < 0.001) was observed, whereas no significant decrease was seen in patients not achieving remission (n = 39). There was a significant difference in the change in the level of MPO (P = 0.01) and HNL (P = 0.02) between patients achieving clinical remission and those who did not, but changes in FC and EDN could not differentiate between these groups. Patients with concomitant systemic corticosteroids at inclusion had lower levels of HNL (P = 0.01) and EDN (P < 0.001) at baseline, compared with patients without corticosteroids.

DISCUSSION: 

Fecal MPO, HNL, and EDN are all promising biomarkers for assessing the treatment outcome of biologics in patients with IBD. Fecal levels of EDN and HNL are significantly affected by corticosteroids indicating a greater sensitivity to the effects of corticosteroids compared with levels of FC and MPO.

Place, publisher, year, edition, pages
Wolters Kluwer, 2023
Keywords
inflammatory bowel disease, fecal biomarkers, biological therapy
National Category
Gastroenterology and Hepatology Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-524612 (URN)10.14309/ctg.0000000000000605 (DOI)001158085800005 ()37256716 (PubMedID)
Funder
Swedish Foundation for Strategic Research, RB13-016Uppsala University
Available from: 2024-03-11 Created: 2024-03-11 Last updated: 2025-02-11Bibliographically approved
Jagarlamudi, K. K., Swinkels, L., Zupan, M., Osredkar, J., Venge, P. & Eriksson, S. (2022). Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples. PLOS ONE, 17(10), Article ID e0275444.
Open this publication in new window or tab >>Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples
Show others...
2022 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 17, no 10, article id e0275444Article in journal (Refereed) Published
Abstract [en]

Thymidine Kinase 1 (TK1) plays an important role in DNA precursor synthesis and serum TK1 activity has been used as a biomarker for prognosis and therapy monitoring of different malignancies. AroCell has developed a dual monoclonal antibody ELISA for determination of TK1 protein in clinical samples. The purpose of the study is to validate the ELISA analytically in relation to the gold standard, [3H]-deoxythymidine (dThd) phosphorylation assay for TK1 activity using sera from patients with different malignancies. The colorimetric TK 210 ELISA was validated analytically by assessment of precision, linearity, interfering substances, and stability. For the clinical validation, serum samples from patients with hematological malignancies (n = 100), breast cancer (n = 56), prostate cancer (n = 70) and blood donors (n = 159) were analyzed using TK 210 ELISA and TK1 activity by [3H]-deoxythymidine (dThd) phosphorylation assay. The sandwich TK 210 ELISA was highly specific for TK1 protein having a detection limit of 0.12 ng/mL, with a functional sensitivity of 0.25 ng/mL. Within-run CVs ranged from 5.5% to 10% and between-run CVs ranged from 5% to 15%. The ratio of observed to expected dilutional parallelism of 5 serum samples was in the range of 80-120%. Samples exhibited stability through four freeze/thaw cycles and 5 days at 4°C. Further, the ROC curve analysis showed that TK 210 ELISA and [3H]-dThd phosphorylation assay had similar sensitivity (62% vs 59%) in hematological malignancies. However, in the case of breast and prostate cancer sera, TK 210 ELISA had higher sensitivity (59% and 44%) compared to [3H]-dThd phosphorylation assay (47% and 25%) at a specificity of 98%. These data demonstrate that the dual monoclonal antibody based AroCell TK 210 ELISA is a robust, accurate and precise tool for measuring TK1 protein in different malignancies that can improve the clinical applications of TK1 as a biomarker in cancer management.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2022
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-489056 (URN)10.1371/journal.pone.0275444 (DOI)000925060900067 ()36201558 (PubMedID)
Available from: 2022-11-26 Created: 2022-11-26 Last updated: 2023-05-03Bibliographically approved
Castro Tejera, V., Öhman, L., Aabakken, L., Fellström, B., Hausken, T., Hovde, Ø., . . . Törnblom, H. (2022). Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.. Alimentary Pharmacology and Therapeutics, 56(6), 968-979
Open this publication in new window or tab >>Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
Show others...
2022 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 56, no 6, p. 968-979Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS).

AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or plcebo once-daily. The primary endpoint was the global assessment of satisfactory relief of IBS symptoms in ≥50% of weeks during intervention. IBS symptoms were also measured with the IBS severity scoring system; immune activity was measured by mucosal patch technology. A post hoc meta-analysis of randomised placebo-controlled trials of mesalazine in IBS was added.

RESULTS: Of 181 included patients, 91 received mesalazine and 90 received placebo. The primary endpoint was met by 32 (36%) patients after mesalazine and 27 (30%) after placebo (p = 0.40). There were no differences in response rates related to IBS subtype or post-infection symptom onset. More reduction of abdominal bloating was noted in the mesalazine group (p = 0.02). The meta-analysis showed no effect of mesalazine on IBS symptoms. No mucosal patch technology measure could predict response to mesalazine, and found no differences in the effects of intervention on levels of immune markers.

CONCLUSIONS: Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.

Place, publisher, year, edition, pages
John Wiley & SonsWiley, 2022
National Category
Clinical Medicine
Identifiers
urn:nbn:se:uu:diva-489057 (URN)10.1111/apt.17182 (DOI)000837473200001 ()35942522 (PubMedID)
Available from: 2022-11-26 Created: 2022-11-26 Last updated: 2025-02-18Bibliographically approved
Backlund, M., Venge, P. & Berntson, L. (2021). A cross-sectional cohort study of the activity and turnover of neutrophil granulocytes in juvenile idiopathic arthritis. Pediatric Rheumatology, 19(1), Article ID 102.
Open this publication in new window or tab >>A cross-sectional cohort study of the activity and turnover of neutrophil granulocytes in juvenile idiopathic arthritis
2021 (English)In: Pediatric Rheumatology, E-ISSN 1546-0096, Vol. 19, no 1, article id 102Article in journal (Refereed) Published
Abstract [en]

Background: The inflammatory process in juvenile idiopathic arthritis (JIA) involves both the innate and the adaptive immune system. The turnover and activity of neutrophil granulocytes may be reflected by proteins secreted from primary or secondary granules and from the cytoplasm of sequestered cells. Our primary aim was to compare the levels of the secondary neutrophil granule protein human neutrophil lipocalin (HNL), in JIA patients and controls, and to explore a possible priming of neutrophils through parallel analyses in plasma and serum. A secondary aim was to relate the levels of HNL to two other well-studied leukocyte proteins, S100A8/A9 and myeloperoxidase (MPO), as well as to clinical aspects of JIA.

Methods: The concentrations of the three biomarkers in serum, two of them also in plasma, were measured using enzyme-linked immunosorbent assay in 37 children with JIA without medical treatment, in high disease activity based on juvenile arthritis disease activity score 27 (JADAS27), 32 children on medical treatment, mainly in lower disease activity, and 16 healthy children. We assessed for differences between two groups using the Mann-Whitney U test, and used the Kruskal-Wallis test for multiple group comparisons. Spearman rank correlation, linear and multiple regression analyses were used for evaluation of associations between biomarker concentrations and clinical scores.

Results: The concentrations of HNL and MPO in serum were significantly increased in children with JIA (p<0.001, p=0.002) compared with healthy children, but we found no difference in the plasma levels of HNL and MPO between children with JIA and controls. The serum concentrations of MPO and HNL were unaffected by medical treatment, but S100A8/A9 was reduced by medical treatment and correlated with JADAS27 in both univariate (r=0.58, p<0.001) and multivariate (r=0.59, p<0.001) analyses.

Conclusions: Neutrophil granulocytes in children with JIA are primed to release primary and secondary granule proteins, without relation to medical treatment, whereas signs of increased turnover and sequestration of neutrophil granulocytes are reduced by treatment. Levels of neutrophil-originating proteins in serum most likely reflect underlying disease activities of JIA.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2021
Keywords
Neutrophil granulocytes, Priming, Granule proteins, Juvenile idiopathic arthritis
National Category
Clinical Medicine Pediatrics
Identifiers
urn:nbn:se:uu:diva-450908 (URN)10.1186/s12969-021-00600-7 (DOI)000671286500003 ()34193192 (PubMedID)
Funder
Gillbergska stiftelsen
Available from: 2021-08-20 Created: 2021-08-20 Last updated: 2025-02-18Bibliographically approved
Venge, P., Eriksson, S. & Pauksen, K. (2021). Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections. JIM - Journal of Immunological Methods, 489, Article ID 112908.
Open this publication in new window or tab >>Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections
2021 (English)In: JIM - Journal of Immunological Methods, ISSN 0022-1759, E-ISSN 1872-7905, Vol. 489, article id 112908Article in journal (Refereed) Published
Abstract [en]

The correct diagnosis of acute infections as to bacteria, mycoplasma or virus is a clinical challenge and has a great impact on the therapeutic decisions. Current diagnostic tests of mycoplasma pneumoniae infections of the respiratory tract such as PCR and serology are either somewhat unreliable or slow and do not entirely meet the clinical needs of accurate and fast diagnosis. The aim of this report was to examine a panel of candidate biomarkers and their capacity to distinguish mycoplasma pneumoniae respiratory infections from respiratory infections caused by either bacterial or virus.

Method: Patients with confirmed etiology of their acute respiratory infections (n = 156) were included of which 28 patients were diagnosed with mycoplasma pneumoniae. Blood was taken before any antibiotics treatment and analysed for Azurocidin (HBP), Calprotectin, CRP, Human Neutrophil Lipocalin (HNL), Interferon gamma-induced Protein 10 kDa (IP-10), Procalcitonin (PCT), Thymidine Kinase 1 (TK1), THE-Related Apoptosis-Inducing Ligand (TRAIL).

Results: Individually the concentrations of IP-10, TK1 and P-HNL distinguished mycoplasma pneumoniae from bacterial infections with AUCs of 0.79-0.85. However, in combination, TK1 with either IP-10 or P-HNL showed an AUC of 0.97-0.95. In the distinction between mycoplasma pneumoniae and viral respiratory infections CRP, Calprotectin and TRAIL showed individual AUCs of 0.94-0.84. Together with either P-HNL dimer or PCT, CRP showed AUCs of 0.97.

Conclusion: Our results indicate that it may be possible to design useful diagnostic algorithms of biomarkers that could help distinguish mycoplasma pneumoniae from respiratory infections caused by bacteria or virus. The development of rapid point-of-care assays based on such algorithms could be clinically useful tools in the therapeutic decision-making.

Place, publisher, year, edition, pages
ElsevierELSEVIER, 2021
National Category
Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-435186 (URN)10.1016/j.jim.2020.112908 (DOI)000608835200001 ()33166548 (PubMedID)
Available from: 2021-02-26 Created: 2021-02-26 Last updated: 2024-01-15Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-5863-790x

Search in DiVA

Show all publications